Latest research on anti-RSV

Humanized monoclonal antibody (IgG1k) produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the F protein of respiratory syncytial virus (RSV). Synagis is a composite of human (95%) and murine (5%) antibody sequences. The human heavy chain sequence was derived from the constant domains of human IgG1 and the variable framework regions of the VH genes Cor (1) and Cess (2). The human lightchain sequence was derived from the constant domain of Ck and the variable framework regions of the VL gene K104 withJk-4. Palivizumab is expressed from a stable murine (mouse) myeloma cell line (NS0). Palivizumab is composed of to heavy chains (50.6 kDa each) and two light chains (27.6 kDa each), contains 1-2% carbohydrate by weight and has a molecular weight of 147.7 kDa +/- 1 kDa (MALDI-TOF)

anti-RSV side effects

Possible reasons for the difference between the Turkish (15) and other studies (5, 16, 17) include: using CLARITHROMYCIN with its greater lung penetration and potential anti-RSV activity (11), differences in sample size, attrition population characteristics, the role of chance, and increased risk of bias associated with small studies. [source, 2015]
Mab b12 signals in this population decreased one-half log within 30 minutes of attachment then steadily declined to near background levels (defined by Synagis negative control measures) by 240 minutes. [source, 2015]
Remarkably, for the first time in healthy humans an Fc-engineered anti-RSV mAb (motavizumab-YTE, M252Y/S254T/T256E) showed a significant serum half-life extension (up to 100 days, two- to fourfold increase), fully confirming in humans the results previously obtained in animal models (19, 26). [source, 2015]
When introduced in an anti-RSV and an anti-IL6 IgG1, these YTE mutations increased the IgG binding to human FcRn by about 10-fold by SPR, resulting in a nearly fourfold increase in serum half-life in cynomolgus monkeys (23, 60). [source, 2015]
However, Ribavirin efficacy against RSV is limited and severe adverse effects, in particular an increased risk of anemia and mitochondrial toxicity (Canonico, 1985; Gilbert and Knight, 1986; Huggins et al., 1991), undermine its clinical use for anti-RSV therapy. [source, 2015]
To evaluate the hypothesis that therapeutic polyclonal immunoglobulin prepared from donor plasma with high titers of anti-RSV IgG may also have evidence of increased humoral immunity against other viral pathogens, RI-002 was compared in aggregate to 10 different lots of commercially available standard polyclonal IVIG products. [source, 2015]
anti-RSV activity of KRGE has a high significance considering the fact that RSV is the most frequent viral cause of respiratory diseases, asthma, and chronic obstructive pulmonary disease exacerbations early and later in life (27). [source, 2014]
Although Th2 immune response confronts efficient anti-RSV response, in a murine RSV-model, IL-4 exerted beneficial effect on the RSV-caused immunopathology by downregulation of inflammatory cytokines [27]. [source, 2014]
To prepare chimeric mAbs for testing, variable regions from a human anti-RSV mAb were used because they would not be expected to bind endogenous ferret proteins, which could affect pharmacokinetics. [source, 2014]
In cases where there was a third mAb administration, anti-RSV was dosed instead (Table II) to reduce the likelihood of interference in mAb detection because of potential monkey anti-idiotype antibodies to anti-growth factor in circulation. [source, 2013]